FDA warned LIV Health/INFINIWELL and DEAL Media/HARMONIA that seven products were sold as unapproved new drugs via disease-treatment claims.
What happened
FDA reviewed the companies’ websites in August–September 2021 and found they took orders for seven products and made claims that the products treat thyroid disease, anxiety, insomnia, high cholesterol, and Alzheimer’s disease. FDA said these claims make the products drugs intended to cure, mitigate, treat, or prevent disease. Because the products are not generally recognized as safe and effective for those uses, FDA called them unapproved new drugs and said they are misbranded because they lack adequate directions for use.
What FDA found
The products are unapproved new drugs because they are not generally recognized as safe and effective for their claimed uses.
section 201(p) [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]The website claims make the products drugs because they are intended to cure, mitigate, treat, or prevent disease.
section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended uses.
section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
What FDA wants
FDA asks the companies to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, with an explanation of each step and supporting documents. If corrective action cannot be completed in that time, they must state the reason and the planned completion time; if they disagree, they must include their reasoning and supporting information.
Who should pay attention
- supplement brands and online sellers making disease-treatment claims
- retailers or marketplaces listing thyroid, sleep, anxiety, or cognitive-support products
- compliance teams reviewing website claims and product labels
This is a summary. Read the original letter on fda.gov.